Report #2848281

Received Jul 2, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 69 yrs
State: FL
Recovered: Recovered
Vaccinated: Jun 30, 2025
Onset: Jun 1, 2025
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	2	946063	IM / LA

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Patient received 2nd dosage of Heplisav-B 26 days after her first dosage. ACIP Guidelines state that patients should receive 2nd dosage of Heplisav-B at least 28 days after 1st dosage.

Current illness

none

Medical history

hypertension

Other medications

amlodipine 5 mg

Allergies

nkda

Lab data

none